With President Donald Trump expected to levy tariffs on pharmaceuticals manufactured outside the United States, industry ...

Compounded versions could make up as much as 40% of the semaglutide market, said Novo Nordisk CEO Lars Fruergaard Jorgensen ...

Billionaire Dalio, head of the world's largest hedge fund, is considered a global authority on investing in China. The bank ...

The bosses of some of the world's biggest companies met with Chinese President Xi Jinping in Beijing on Friday.

When looking for investment inspiration, it's a great idea to consider what some of the world's most successful investors are ...

The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...

INDIANAPOLIS: Drugmaker Eli Lilly and Company’s SVP and chief communications officer, Kathryn Beiser, has resigned. Beiser ...

The way people are accessing GLP-1 medications Semaglutide and Tirzepatide is going to become very limited after the drugs were taken off the FDA’s shortage list.

Explore what to expect now that the Hims & Hers stock price now that it has crashed hard in the past few weeks.

Eli Lilly and Novo Nordisk are in a global battle for dominance in the weight loss space. BioSpace takes a look at the ...

Eli Lilly’s Global CEO David Ricks revealed that the pharma giant might manufacture its weight-loss blockbuster, Mounjaro, in ...

Customers who struggle to afford the $1,000-plus list price for weight-loss drugs Zepbound and Wegovy can buy now and pay ...